Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

Abstract

Samy Suissa,1,2 Sophie Dell’Aniello,1 Pierre Ernst1,2 1Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada; 2Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, CanadaCorrespondence: Samy Suissa, Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine, H-461, Montreal, Québec, H3T 1E2, Canada, Tel [phone], Fax [phone], Email [email protected]: Randomized trials report that single-inhaler triple therapy is more effective than dual bronchodilators at reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this effect may have been influenced by the forced withdrawal of inhaled corticosteroids (ICS) at randomization. We used an adaptive selection new-user design to compare single-inhaler triple therapy with dual bronchodilators in real-world clinical practice.Patients and Methods: We identified a cohort of COPD patients, 40 years or older, treated during 2017– 2020, from the United Kingdom’s Clinical Practice Research Datalink, a real-world practice setting. ICS-naïve patients initiating single-inhaler triple therapy or dual bronchodilators were compared on the incidence of COPD exacerbation and pneumonia over one year, after adjustment by propensity score weighting.Results: The cohort included 4106 new users of single-inhaler triple therapy and 29,702 of dual bronchodilators. Single-inhaler triple therapy was the first maintenance treatment in 44% of the users and 43% had no COPD exacerbations in the prior year. The adjusted hazard ratio (HR) of a first moderate or severe exacerbation with triple therapy relative to dual bronchodilators was 1.08 (95% confidence interval (CI): 1.00– 1.16). Among patients with two or more prior exacerbations the HR was 0.83 (95% CI: 0.74– 0.92), while for those with prior asthma diagnosis it was 0.86 (95% CI: 0.70– 1.06) and with blood eosinophil count > 300 cells/μL it was 0.89 (95% CI: 0.76– 1.05). The incidence of severe pneumonia was increased with triple therapy (HR 1.50; 95% CI: 1.29– 1.75).Conclusion: In a real-world setting of COPD treatment among ICS-naïve patients, thus unaffected by ICS withdrawal, single-inhaler triple therapy was not more effective than dual bronchodilators at reducing the incidence of exacerbation, except among patients with multiple exacerbations. Single-inhaler triple therapy should be initiated mainly in patients with multiple exacerbations while, for most others, dual bronchodilators are just as effective whilst avoiding the excess risk of severe pneumonias.Keywords: cohort studies, COPD exacerbation, pneumonia, propensity scores, real-world evidence

Keywords

• cohort studies
• copd exacerbation
• pneumonia
• propensity scores
• real-world evidence.